What does HRD status mean for Breast Cancer treatment

HRD Status in Breast Cancer Treatment

HRD stands for Homologous Recombination Deficiency — this is a measure of how well your cancer cells can repair certain types of DNA damage. Let me explain what this means and why it matters for your treatment.

How HRD Works (The Clinical Reasoning)

Your cells normally have two main ways to fix broken DNA:

• Homologous recombination (HR) — a precise, high-fidelity repair system
• Other backup repair pathways — less precise but still functional

When cancer cells have HRD, their homologous recombination repair system is broken or weakened. This creates a vulnerability that doctors can exploit with specific drugs.

Why Doctors Test for HRD

Oncologists test for HRD status because it predicts how well certain treatments will work:

PARP Inhibitors (like olaparib/Lynparza) are drugs that block a backup DNA repair pathway. When cancer cells already have a broken HR system AND you block their backup repair, the cancer cells can't fix their DNA and die.

According to NCCN Guidelines for Invasive Breast Cancer, olaparib may be added as adjuvant therapy (treatment after surgery) in certain cases, particularly for HR+ HER2- breast cancers with specific risk factors.

HRD Status Categories

HRD-Positive (HRD+):

• Cancer cells have deficient homologous recombination repair
• Often associated with BRCA1/2 mutations (inherited genetic changes)
• May also occur from other genetic alterations (PTEN loss, RAD51 mutations, etc.)
• More likely to respond to PARP inhibitors

HRD-Negative (HRD-):

• Cancer cells have functional HR repair
• Less likely to benefit from PARP inhibitor monotherapy
• May still benefit from other treatment approaches

Treatment Implications

For HRD-Positive Breast Cancer:

• PARP inhibitors become a potential treatment option
• These drugs are FDA-approved for certain breast cancer subtypes
• Often used in combination with other therapies or as maintenance treatment

For HRD-Negative Breast Cancer:

• PARP inhibitors alone are typically not recommended
• Your doctor will focus on other treatment pathways based on your HR and HER2 status

Questions to Ask Your Oncologist

If HRD testing has been done or is being considered, ask:

1. "Has my tumor been tested for HRD status, and what were the results?"
2. "Based on my HRD status and other biomarkers, am I a candidate for PARP inhibitor therapy?"
3. "If I'm HRD-positive, would a PARP inhibitor be recommended as part of my treatment plan?"
4. "What are the potential side effects of PARP inhibitors, and how would they be managed?"
5. "Are there clinical trials available that might be relevant to my specific HRD and receptor status?"

Important Context

According to NCCN Guidelines, HRD testing is particularly relevant for:

• Patients with BRCA1/2 mutations
• Those with HR+ HER2- breast cancer being considered for additional therapies beyond standard endocrine therapy
• Patients with metastatic breast cancer where additional treatment options are being explored

Your complete treatment plan depends on multiple factors: your HRD status, hormone receptor status (HR+/HR-), HER2 status, stage of disease, and your overall health. Your oncologist will integrate HRD results with all other clinical information to determine the best approach for YOUR specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.